Form 4: Boston Scientific Director Wichmann Receives Annual Equity Award

David S. Wichmann, a director at Boston Scientific, acquired 2,901 shares of common stock as an annual equity award on May 9, 2024.

Summary

• On May 9, 2024, David S. Wichmann, a director of Boston Scientific, acquired 2,901 shares of Boston Scientific common stock.
• The acquisition was an annual equity award in the form of restricted stock.
• The restricted stock vests in full upon the next annual meeting of stockholders.
• Following the transaction, Wichmann beneficially owns 39,501 shares of Boston Scientific common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard equity award, indicating confidence in the company's future, but it's not a major event.

Positives

• The equity award aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining investor confidence.

Stakeholder Impact

• The equity award aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Next Steps

• The restricted stock will vest upon the next annual meeting of stockholders.

Key Dates